Hypertensive Disorders in Pregnancy: Pathophysiology, Diagnostic Criteria, Clinical Management Protocols, and Long-Term Maternal-Neonatal Sequelae

1. Bharti Chavhan

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

Abstract

Hypertensive disorders in pregnancy represent a leading cause of maternal and perinatal morbidity and mortality worldwide, complicating approximately five to ten percent of all gestations. These disorders encompass a heterogeneous spectrum of clinical conditions, including chronic hypertension, gestational hypertension, preeclampsia-eclampsia, and chronic hypertension superimposed by preeclampsia. The pathophysiological hallmark of preeclampsia centers on abnormal placentation during the first trimester, characterized by inadequate trophoblastic invasion of maternal spiral arteries, leading to placental ischemia, systemic endothelial dysfunction, release of anti-angiogenic factors into the maternal circulation, and heightened systemic inflammatory responses. Diagnostic stratification has evolved beyond the classic triad of hypertension, proteinuria, and dependent edema, incorporating novel angiogenic biomarkers such as the soluble fms-like tyrosine kinase-1 to placental growth factor ratio, alongside assessment of end-organ dysfunction involving the hepatic, renal, and central nervous systems. Management protocols depend strictly on gestational age at onset and severity of disease, ranging from outpatient surveillance in mild gestational hypertension to inpatient stabilization, administration of antenatal corticosteroids for fetal lung maturation, magnesium sulfate for seizure prophylaxis in preeclampsia with severe features, and timely delivery. Long-term implications extend beyond the acute postpartum period, as survivors face substantially elevated lifetime risks of chronic cardiovascular disease, stroke, and chronic kidney disease. Standardizing clinical screening, implementing targeted aspirin prophylaxis for high-risk cohorts, and optimizing postpartum surveillance represent vital strategies for mitigating the global burden of pregnancy-related hypertensive pathology.

Introduction

Hypertensive disorders in pregnancy constitute one of the most formidable challenges in modern obstetrics and maternal-fetal medicine. They contribute significantly to the global burden of maternal mortality, maternal intensive care unit admissions, iatrogenic preterm births, and perinatal morbidity. The clinical spectrum spans mild blood pressure elevations detected late in gestation to catastrophic multi-organ failure characterized by seizures, intracranial hemorrhage, HELLP syndrome, and acute renal failure. Despite centuries of clinical observation and decades of intensive biomedical research, these disorders remain among the most complex and unpredictable pathologies of human reproduction.

The classification framework established by professional organizations, including the American College of Obstetricians and Gynecologists and the International Society for the Study of Hypertension in Pregnancy, categorizes hypertensive disorders into four distinct clinical entities: chronic hypertension, gestational hypertension, preeclampsia-eclampsia, and chronic hypertension with superimposed preeclampsia. Chronic hypertension is defined as blood pressure of 140 millimeters of mercury systolic or 90 millimeters of mercury diastolic occurring prior to conception or before twenty weeks of gestation. Gestational hypertension involves the new onset of hypertension after twenty weeks of gestation in the absence of proteinuria or systemic signs of end-organ dysfunction, with blood pressure resolving by twelve weeks postpartum. Preeclampsia represents a multi-system, pregnancy-specific syndrome defined by new-onset hypertension coupled with proteinuria or evidence of maternal end-organ dysfunction arising after twenty weeks of gestation. Eclampsia is defined by the development of tonic-clonic seizures in a woman with preeclampsia that cannot be attributed to other neurological conditions. Finally, chronic hypertension with superimposed preeclampsia describes patients with pre-existing chronic hypertension who develop worsening blood pressure control accompanied by new-onset proteinuria or signs of end-organ damage in the latter half of pregnancy.

The epidemiological distribution of these disorders varies across geographic, racial, and socioeconomic divides, influenced by rising maternal age, increasing prevalence of pre-existing metabolic comorbidities such as obesity and type 2 diabetes, and disparities in healthcare access. The pathophysiology of preeclampsia, in particular, has shifted from a simplistic model of placental hypoperfusion to a sophisticated paradigm involving immune maladaptation, genetic predisposition, angiogenic imbalance, and generalized maternal endothelial injury.

The primary objective of this review is to provide an exhaustive, evidence-based evaluation of hypertensive disorders in pregnancy using a structured IMRAD format. This paper examines the etiological mechanisms and molecular pathways driving endothelial dysfunction, evaluates contemporary diagnostic criteria and biomarker utility, delineates acute and expectant management protocols across varying gestational windows, and summarizes the acute and long-term health sequelae for both mother and offspring.

Methods

To systematically compile and synthesize contemporary clinical literature addressing hypertensive disorders in pregnancy, an extensive literature retrieval strategy was executed. Major medical and scientific databases, including PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, were searched to identify high-quality studies, randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines published by leading international obstetric and gynecological societies.

Study Selection Parameters

The literature review prioritized peer-reviewed publications focusing on human singleton and multifetal gestations complicated by chronic hypertension, gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome. Eligible articles investigated pathophysiological mechanisms involving angiogenic factors, genetic susceptibility, uterine spiral artery remodeling, diagnostic accuracy of blood pressure measurement and urinary protein quantification, predictive value of serum biomarkers, pharmacological efficacy of antihypertensive agents, magnesium sulfate neuroprotection protocols, timing of delivery, and postpartum cardiovascular risk tracking.

Data Synthesis and Analytical Framework

Extracted data were organized into thematic domains corresponding to the core sections of the review. Pathophysiological data were synthesized by molecular pathway, focusing on the imbalance between pro-angiogenic and anti-angiogenic circulating proteins. Diagnostic criteria were evaluated based on sensitivity, specificity, and positive predictive value for established and emerging clinical metrics. Therapeutic interventions were appraised by evaluating relative risk reductions, maternal safety profiles, and perinatal outcomes across gestational age strata.

Results

Pathophysiology and Etiological Mechanisms

The pathophysiology of gestational hypertension and chronic hypertension is primarily rooted in pre-existing or pregnancy-induced alterations in systemic vascular resistance, sympathetic nervous system tone, and renal sodium handling. However, the pathophysiology of preeclampsia is uniquely complex, unfolding in a two-stage model: abnormal placentation during early gestation followed by maternal systemic endothelial dysfunction in the second half of pregnancy.

During normal first-trimester placentation, extravillous trophoblasts invade the maternal decidual and myometrial segments of the spiral arteries. These trophoblasts remodel high-resistance, muscular maternal spiral vessels into low-resistance, high-capacitance vascular conduits capable of supplying the expanding fetoplacental unit with adequate maternal blood flow. In preeclampsia, this process is shallow and incomplete. The physiological transformation of the spiral arteries fails to occur, leaving the vessels narrow and abnormally reactive. This anatomical defect results in intermittent placental hypoperfusion, oxidative stress, and ischemia within the intervillous space.

Hypoxic placental tissue responds by releasing a cascade of cellular debris, inflammatory cytokines, syncytiotrophoblast microparticles, and anti-angiogenic proteins into the maternal circulation. Among these factors, soluble fms-like tyrosine kinase-1 plays a central pathogenic role. Soluble fms-like tyrosine kinase-1 acts as a decoy receptor that binds and neutralizes circulating pro-angiogenic proteins, specifically vascular endothelial growth factor and placental growth factor. Under normal conditions, vascular endothelial growth factor and placental growth factor promote endothelial health, vasodilation, and vascular repair. The overexpression and excessive release of soluble fms-like tyrosine kinase-1 in preeclampsia leads to a profound deficit in free pro-angiogenic factors, resulting in widespread maternal endothelial cell injury, loss of endothelium-dependent vasodilation, enhanced vascular permeability, and microvascular thrombosis.

This generalized endothelial dysfunction manifests across multiple maternal organ systems. In the renal vasculature, endothelial injury causes swelling of the glomerular capillary endothelial cells—a lesion termed glomerular endotheliosis—which impairs filtration and leads to proteinuria, hyperuricemia, and sodium retention. In the hepatic vasculature, microvascular ischemia and fibrin deposition lead to periportal necrosis and subcapsular hemorrhage, culminating in the elevated liver enzymes characteristic of HELLP syndrome. Within the cerebral circulation, loss of autoregulation and endothelial disruption can cause vasogenic edema, petechial hemorrhages, and cerebral hyperperfusion, triggering visual disturbances, severe headaches, and eclamptic seizures.

Diagnostic Stratification and Clinical Evaluation

Accurately diagnosing hypertensive disorders in pregnancy requires rigorous standardization of blood pressure measurement techniques. Hypertension in pregnancy is universally defined as a systolic blood pressure of 140 millimeters of mercury or higher, or a diastolic blood pressure of 90 millimeters of mercury or higher, confirmed on two separate occasions at least four hours apart (or within a shorter interval if severe-range blood pressures of 160 over 110 millimeters of mercury or higher are observed). Blood pressure should be measured with the patient in a seated or semi-recumbent position using an appropriately sized cuff after a period of rest.

The clinical differentiation between gestational hypertension and preeclampsia rests upon the presence of systemic manifestations of the disease. While gestational hypertension involves isolated blood pressure elevation developing after twenty weeks of gestation, preeclampsia requires the concurrent presence of proteinuric or non-proteinuric end-organ dysfunction. Proteinuria is traditionally defined as urinary excretion of 300 milligrams or more of protein in a twenty-four-hour urine collection, or a protein-to-creatinine ratio of 0.3 or higher on a random urine specimen, or a persistent reading of 2 plus on standard urine dipstick analysis. However, contemporary diagnostic guidelines recognize that preeclampsia can be diagnosed in the absence of proteinuria if hypertension is accompanied by any of the following severe end-organ features: new-onset thrombocytopenia (platelet count less than 100,000 per microliter), impaired liver function indicated by serum transaminases concentrations elevated to twice normal limits, progressive renal insufficiency manifested by serum creatinine concentrations greater than 1.1 milligrams per deciliter or a doubling of serum creatinine in the absence of other renal disease, pulmonary edema, or new-onset cerebral or visual disturbances such as persistent headaches or scotomata.

The clinical landscape of preeclampsia is further divided into preeclampsia without severe features and preeclampsia with severe features. The presence of any severe-range blood pressure reading (160 over 110 millimeters of mercury or higher) or any of the aforementioned laboratory or clinical end-organ abnormalities immediately categorizes the patient as having preeclampsia with severe features, necessitating inpatient evaluation and expedited management protocols.

Emerging diagnostic tools incorporate circulating angiogenic biomarkers to refine risk stratification and diagnostic certainty, particularly in patients presenting with ambiguous signs or symptoms remote from term. The ratio of soluble fms-like tyrosine kinase-1 to placental growth factor serves as a powerful biochemical indicator. A low soluble fms-like tyrosine kinase-1 to placental growth factor ratio has a high negative predictive value, effectively ruling out the development of short-term preeclampsia in women presenting with suspected signs, thereby safely avoiding unnecessary hospital admissions. Conversely, an elevated ratio supports the diagnosis of placental dysfunction and correlates with a higher likelihood of adverse maternal and neonatal outcomes requiring delivery.

Management Protocols and Therapeutic Interventions

Management strategies for hypertensive disorders in pregnancy are dictated by gestational age at diagnosis, severity of blood pressure elevation, and presence or absence of maternal end-organ dysfunction or fetal compromise. The overarching goal of management is to prevent maternal morbidity and mortality—such as stroke, eclampsia, and organ failure—while optimizing neonatal outcomes by balancing the risks of prematurity against the risks of continuing an intrauterine pregnancy.

For women with chronic hypertension or gestational hypertension without severe features, outpatient surveillance is standard of care, provided maternal laboratory evaluations and fetal assessment parameters remain reassuring. Outpatient monitoring includes bi-weekly blood pressure checks, serial laboratory evaluations for renal and hepatic function, and fetal surveillance via ultrasound assessment of fetal growth and amniotic fluid volume, alongside antenatal fetal heart rate testing. Antihypertensive therapy is generally initiated for persistent severe chronic hypertension (sustained blood pressure of 160 over 110 millimeters of mercury or higher). For non-severe chronic hypertension, consensus guidelines support maintaining blood pressure targets between 130 and 140 millimeters of mercury systolic and 80 and 90 millimeters of mercury diastolic using first-line oral agents such as labetalol, nifedipine extended-release, or methyldopa. Routine initiation of antihypertensive therapy for mild gestational hypertension without severe features remains debated, as clinical trials have demonstrated that while treatment reduces maternal progression to severe hypertension, it does not necessarily alter the overall incidence of adverse perinatal outcomes.

When a patient is diagnosed with preeclampsia with severe features prior to thirty-four weeks of gestation, expectant management—often referred to as delayed delivery—may be considered in specialized tertiary care centers under intensive inpatient surveillance, provided neither maternal nor fetal condition is acutely unstable. Expectant management allows for the administration of antenatal corticosteroids to accelerate fetal lung maturation and reduce the incidence of respiratory distress syndrome, intraventricular hemorrhage, and necrotizing enterocolitis. Betamethasone administered as two intramuscular doses of twelve milligrams twenty-four hours apart represents the standard corticosteroid regimen. Throughout expectant management, continuous maternal monitoring includes serial assessment of symptoms, blood pressure tracking, continuous or intermittent fetal monitoring, and frequent laboratory testing of complete blood counts, hepatic transaminases, and renal parameters.

Immediate delivery is mandatory for any patient with preeclampsia with severe features who has reached or exceeded thirty-four weeks of gestation, as well as for patients at any gestational age presenting with uncontrollable severe hypertension refractory to multi-agent medical therapy, eclampsia, pulmonary edema, placental abruption, disseminated intravascular coagulation, persistent neurological symptoms, non-reassuring fetal status, or fetal demise.

Intrapartum and immediate postpartum management require rigorous medical protocols to prevent acute complications. For patients with severe-range blood pressures during labor or inpatient stabilization, acute antihypertensive therapy is administered promptly to lower blood pressure and reduce the risk of maternal cerebrovascular accident. First-line acute agents include intravenous labetalol (administered as sequential boluses of increasing dosage), intravenous hydralazine, or oral nifedipine immediate-release capsules.

Magnesium sulfate administration is indicated for the prevention and treatment of eclamptic seizures in patients with preeclampsia with severe features. Magnesium acts as a central nervous system NMDA receptor antagonist and cerebral vasodilator, significantly reducing the relative risk of eclamptic seizures without causing significant neonatal depression when maintained within therapeutic serum ranges. Standard magnesium sulfate protocols involve an intravenous loading dose of four to six grams administered over twenty minutes, followed by a continuous maintenance infusion of one to two grams per hour. In cases of acute eclamptic convulsions, magnesium sulfate serves as the primary anticonvulsant agent to terminate seizures and prevent recurrence. Monitoring for magnesium toxicity—manifested by loss of deep tendon reflexes, respiratory depression, and oliguria—is essential, with intravenous calcium gluconate kept immediately available as a specific reversal agent.

Maternal-Neonatal Outcomes and Postpartum Sequelae

The immediate and long-term outcomes associated with hypertensive disorders in pregnancy reflect profound systemic implications for both maternal and neonatal health.

Neonatal outcomes are heavily influenced by gestational age at delivery and the degree of uteroplacental insufficiency. Infants born to mothers with severe preeclampsia face elevated risks of iatrogenic or spontaneous preterm birth, intrauterine growth restriction, oligohydramnios, placental abruption, and neonatal intensive care unit admission. Chronic intrauterine hypoxia resulting from abnormal spiral artery remodeling can lead to asymmetrical fetal growth restriction, placing the neonate at risk for perinatal asphyxia, meconium aspiration syndrome, and neonatal hypoglycemia. Surviving preterm infants remain vulnerable to respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis.

Maternal acute morbidity encompasses severe short-term complications, including eclampsia, HELLP syndrome, acute kidney injury, pulmonary edema, posterior reversible encephalopathy syndrome, and cerebrovascular hemorrhage. Stroke remains one of the leading causes of maternal mortality associated with preeclampsia, underscoring the critical necessity of aggressive acute blood pressure control.

Postpartum management requires vigilant surveillance, as the physiological changes of preeclampsia do not immediately resolve upon delivery. Up to twenty to thirty percent of eclamptic seizures and new-onset preeclampsia presentations occur in the postpartum period, frequently within the first forty-eight hours after delivery, though delayed postpartum preeclampsia can manifest up to six weeks postpartum. Blood pressure typically peaks within the first three to six days following delivery due to the mobilization of extravascular fluid into the intravascular space. Antihypertensive therapy must be tapered gradually, and patients must be educated on warning signs such as persistent headaches, visual changes, and right upper quadrant pain.

In the long term, epidemiological evidence firmly establishes hypertensive disorders in pregnancy—particularly preeclampsia and pregnancies complicated by fetal growth restriction or preterm delivery—as independent major risk factors for future cardiovascular disease. Women with a history of preeclampsia exhibit a significantly increased lifetime risk of developing chronic hypertension, ischemic heart disease, stroke, heart failure, and thromboembolic events compared to normotensive counterparts. Furthermore, a history of preeclampsia is associated with a two-fold increased risk of chronic kidney disease and end-stage renal disease later in life. Consequently, professional societies recommend structured long-term cardiovascular risk factor screening, lifestyle modification counseling, and ongoing blood pressure monitoring for women with a history of hypertensive pregnancy complications.

Discussion

The management of hypertensive disorders in pregnancy requires balancing diagnostic precision, risk stratification, and timely therapeutic intervention. As synthesized in this review, these disorders represent a complex spectrum of vascular and placental pathologies characterized by widespread maternal endothelial dysfunction and multi-organ involvement.

The pathogenesis of preeclampsia, framed by early-onset abnormal placentation and the subsequent release of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1, highlights the limitation of viewing preeclampsia as a purely maternal disease. The placenta plays a central endocrine and inflammatory role in initiating maternal vascular injury. Recognizing this biological mechanism has paved the way for advanced diagnostic markers, including angiogenic factor ratios that enhance clinical decision-making and diagnostic certainty in ambiguous presentations.

Diagnostic protocols have evolved to recognize that preeclampsia can present safely without overt proteinuria, provided critical end-organ dysfunction involving hematologic, hepatic, or neurological systems is identified. This broadened diagnostic framework ensures that patients presenting with atypical symptoms are not delayed in receiving appropriate inpatient evaluation and monitoring.

Therapeutic management relies on judicious use of antihypertensive medications, standardized magnesium sulfate protocols for seizure prophylaxis, and careful timing of delivery. While expectant management under rigorous tertiary care surveillance can significantly improve neonatal outcomes in preterm preeclampsia, clinicians must maintain vigilance for signs of maternal decompensation or fetal distress, ensuring that delivery is expedited when the risks of continuing pregnancy outweigh potential benefits.

Finally, the recognition of hypertensive disorders in pregnancy as sentinel events for future maternal cardiovascular and renal health represents a paradigm shift in modern medicine. Transitioning from acute intrapartum care to lifelong cardiovascular risk reduction, lifestyle optimization, and structured postpartum monitoring is essential to protect women's long-term health.

Conclusion

Hypertensive disorders in pregnancy remain a major determinant of global maternal and perinatal morbidity and mortality. Characterized by diverse pathophysiological mechanisms ranging from chronic vascular dysfunction to abnormal placentation, systemic endothelial injury, and anti-angiogenic imbalance, these conditions require meticulous clinical management. Accurate diagnosis utilizing standardized blood pressure measurement, laboratory assessment of end-organ function, and emerging biomarker assays enables clinicians to stratify risk effectively.

Evidence-based interventions—such as targeted low-dose aspirin prophylaxis, outpatient surveillance for mild disorders, inpatient expectant management with antenatal corticosteroids for preterm preeclampsia, acute blood pressure control, and magnesium sulfate seizure prophylaxis—have improved maternal and neonatal survival. Recognizing that hypertensive pregnancy complications serve as independent risk factors for lifetime cardiovascular and renal disease underscores the necessity for comprehensive postpartum surveillance and lifelong health optimization.

References

1.     American College of Obstetricians and Gynecologists. (2020). Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics & Gynecology, 135(6), e237–e260. https://doi.org/10.1097/AOG.0000000000003891

2.     Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M., Brennecke, S. P., Stepan, H., Allegranza, D., Dilba, P., Schoedl, M., Hund, M., & Thadhani, R. (2016). Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. New England Journal of Medicine, 374(1), 13–22. https://doi.org/10.1056/NEJMoa1414838

3.     Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishii, S. (2018). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension, 72(1), 24–43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803

4.     Rana, S., Lemoine, E., Granger, J. P., & Karumanchi, S. A. (2019). Preeclampsia: Pathophysiology, challenges, and perspectives. Circulation Research, 124(7), 1094–1112. https://doi.org/10.1161/CIRCRESAHA.118.313276

5.     Rolnik, D. L., Wright, D., Poon, L. C., O'Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., Molina, F. S., Persico, N., Jani, J. C., Plasencia, W., Papaioannou, G., Tenuta, R., Hecher, K., Nicolaides, K. H., & ASPRE Trial. (2017). Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine, 377(7), 613–622. https://doi.org/10.1056/NEJMoa1704559

6.     Magee, L. A., von Dadelszen, P., Rey, E., Ross, S., Asztalos, E., Murphy, K. E., Menzies, J., Sanchez, J., Singer, J., Gafni, A., Gruslin, A., Helewa, M., Hutton, E., Lee, S. K., Lee, T., Logan, A. G., Ganzevoort, W., Welch, R., Thornton, J. G., & CHIPS Study Group. (2015). Less-tight versus tight control of hypertension in pregnancy. New England Journal of Medicine, 372(5), 407–417. https://doi.org/10.1056/NEJMoa1404595

7.     Redman, C. W., & Sargent, I. L. (2010). Latest advances in understanding preeclampsia. Science, 308(5728), 1592–1594. https://doi.org/10.1126/science.1111726

8.     Chappell, L. C., Cluver, C. A., Kingdom, J., & Tong, S. (2021). Preeclampsia. The Lancet, 398(10301), 341–354. https://doi.org/10.1016/S0140-6736(20)32335-7

9.     Ghulmiyyah, L., & Sibai, B. (2012). Maternal mortality from preeclampsia/eclampsia. Seminars in Perinatology, 36(1), 56–59. https://doi.org/10.1053/j.semperi.2011.09.011

10.  Wu, P., Haththotuwa, R., Kwok, C. S., Babu, A., Kotronias, R. A., Rushton, C., Zaman, A., Fryer, A. A., Kadam, U., Chew-Graham, C. A., & Mamas, M. A. (2017). Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes, 10(2), e003497.

11.  Vikse, B. E., Irgens, L. M., Leivestad, T., Skjaerven, R., & Iversen, B. M. (2008). Preeclampsia and the risk of end-stage renal disease. New England Journal of Medicine, 359(8), 800–809. https://doi.org/10.1056/NEJMoa076790

12.  Sibai, B. M. (2004). Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics & Gynecology, 102(1), 181–192. https://doi.org/10.1097/01.AOG.0000078879.48913.be

13.  Tranquilli, A. L., Dekker, G., Magee, L., Roberts, J., Sibai, B. M., Steyn, W., Zeeman, G. G., & von Dadelszen, P. (2014). The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertension, 4(2), 97–104. https://doi.org/10.1016/j.preghy.2014.02.001

14.  Hutcheon, J. A., Lisonkova, S., & Joseph, K. S. (2011). Epidemiology of preeclampsia and the other hypertensive disorders of pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology, 25(4), 391–403. https://doi.org/10.1016/j.bpobgyn.2011.01.006

Thadhani, R., Kisner, T., Hagmann, E., Boss, C., Nossov, V., Pearlstein, J., Wang, J., Shaikhouni, S., Sachs, B., Yin, D. L., Jiang, J., Hunt, J., Murphy, S. P., Zeller, R., Segall, M. A., Axelrod, I., Wright, E., Lindheimer, M., Karumanchi, S. A., & Sukhatme, V. P. (2004). Pilot trial of therapeutic apheresis in preeclampsia. Obstetrics & Gynecology, 104(5 Pt 1), 956–964. https://doi.org/10.1097/01.AOG.0000142713.88072.e9